Latest Approaches for the Treatment of Spasticity and Autonomic Dysreflexia in Chronic Spinal Cord Injury

Neurotherapeutics

Volumn 8, Issue 2, 2011, Pages 274-282

  Rabchevsky, Alexander G ^a   Kitzman, Patrick H ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

bradycardia; clinical interventions; hypertension; pharmacological; Spasms; spinal cord injury

Indexed keywords

ACETYLCHOLINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCIUM CHANNEL; CANNABINOID; CLONIDINE; DANTROLENE; DIAZEPAM; DIAZOXIDE; GABAPENTIN; HYDRALAZINE; MECAMYLAMINE; NABILONE; NEUROPEPTIDE; NIFEDIPINE; NITRATE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PHENYLEPHRINE; PRAZOSIN; PREGABALIN; PROPRANOLOL; SNARE PROTEIN; TERAZOSIN; TIZANIDINE; VESICULAR ACETYLCHOLINE TRANSPORTER;

ACETYLCHOLINE RELEASE; ADVERSE DRUG REACTION; ANALGESIA; ASTHENIA; ATAXIA; AUTONOMIC DYSREFLEXIA; BLADDER DISTENSION; BRADYCARDIA; CHOLINERGIC TRANSMISSION; CHRONIC DISEASE; CLOSTRIDIUM BOTULINUM; CONSTIPATION; DECUBITUS; DEPRESSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TOLERABILITY; ENDOCYTOSIS; EPILEPSY; FATIGUE; HALLUCINATION; HUMAN; HYPERPOLARIZATION; HYPERTENSION; HYPOTENSION; INCIDENCE; INGROWN NAIL; INSOMNIA; INTESTINE DISTENSION; INTOXICATION; INTRATHECAL BACLOFEN WITHDRAWAL SYNDROME; MEAN ARTERIAL PRESSURE; MENTAL DISEASE; MINIPUMP; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NEUROMUSCULAR SYNAPSE; NEUROPATHIC PAIN; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SPASTICITY; SPINAL CORD INJURY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; VASOCONSTRICTION; XEROSTOMIA;

ANIMALS; AUTONOMIC DYSREFLEXIA; CHRONIC DISEASE; HUMANS; MUSCLE SPASTICITY; SPINAL CORD INJURIES;

EID: 79955050640     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13311-011-0025-5     Document Type: Review

References (98)

1. Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma 2004; 21: 1371-1383.
2. Kitzman P. Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat. Exp Neurol 2006; 197: 407-419.
3. Karlsson AK. Autonomic dysreflexia. Spinal Cord 1999; 37: 383-391.
4. Rabchevsky AG. Segmental organization of spinal reflexes mediating autonomic dysreflexia after spinal cord injury. Prog Brain Res 2006; 152: 265-274.
5. Kewalramani LS. Autonomic dysreflexia in traumatic myelopathy. Am J Phys Med 1980; 59: 1-21.
6. Harati Y. Autonomic disorders associated with spinal cord injury. In: Low PA, ed. Clinical autonomic disorders, 2nd edit. Philadelphia: Lippincott-Raven; 1997, 455-461.
7. Krassioukov AV, Furlan JC, Fehlings MG. Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma 2003; 20: 707-716.
8. Snow JC, Sideropoulos HP, Kripke BJ, Freed MM, Shah NK, Schlesinger RM. Autonomic hyperreflexia during cystoscopy in patients with high spinal cord injuries. Paraplegia 1978; 15: 327-332.
9. Blackmer J. Rehabilitation medicine: 1. Autonomic dysreflexia. CMAJ 2003; 169: 931-935.
10. Pathak MS, Nguyen HT, Graham HK, Moore AP. Management of spasticity in adults: practical application of botulinum toxin. Eur J Neurol 2006; 13(suppl 1): 42-50.
11. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010; 46: 401-410.
12. Young RR. Baclofen. Arch Neurol 1977; 34: 722.
13. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981; 304: 96-99.
14. Yang K, Feng Y, Li Y. Baclofen inhibition of dorsal root-evoked inhibitory postsynaptic currents in substantia gelatinosa neurons of rat spinal cord slice. Brain Res 2001; 900: 320-323.
15. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;(9 suppl 1): 30-34; discussion 53-61.
16. Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12: 793-816, vii.
17. Jamous A, Kennedy P, Psychol C, Grey N. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia 1994; 32: 349-353.
18. Kirshblum S. Treatment alternatives for spinal cord injury related spasticity. J Spinal Cord Med 1999; 22: 199-217.
19. Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000; Issue 2. Art. No.: CD001131. doi: 10. 1002/14651858. CD001131.
20. Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 2001; 39: 413-419.
21. Coffey JR, Cahill D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993; 78: 226-232.
22. Ivanhoe CB, Tilton AH, Francisco GE. Intrathecal baclofen therapy for spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12: 923-938, viii-ix.
23. Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004; 75: 1553-1557.
24. Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. Ann Phys Rehabil Med 2009; 52: 746-756.
25. Soni BM, Mani RM, Oo T, Vaidyanathan S. Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature. Spinal Cord 2003; 41: 586-589.
26. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83: 735-741.
27. Palmeri A, Wiesendanger M. Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2-adrenergic agonist in rats: a possible mechanism for an alpha 2-mediated muscle relaxation. Neuroscience 1990; 34: 177-187.
28. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435-452.
29. Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine (Phila Pa 1976) 2001; 26(24 suppl): S146-S160.
30. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-495.
31. Mirbagheri MM, Chen D, Rymer WZ. Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique. J Neuroeng Rehabil 2010; 7: 29.
32. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13(suppl 4): 1-9.
33. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-596.
34. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43(suppl 1): S16-24.
35. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999; 354: 259-268.
36. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001; 248(suppl 1): 3-10.
37. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682-686.
38. Levendoglu F, Ogun CO, Ozerbil O, Ogun TC, Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine (Phila Pa 1976). 2004; 29: 743-751.
39. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-1937.
40. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-1842.
41. Wheeler G. Gabapentin. Pfizer. Curr Opin Investig Drugs 2002; 3: 470-477.
42. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94: 1131-1139.
43. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 2007; 100: 1289-1299.
44. Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol 2004; 141: 574-579.
45. Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001; 134: 237-240.
46. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000; 85: 405-414.
47. Tran-Van-Minh A, Dolphin AC. The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2. J Neurosci. 2010; 30: 12856-12867.
48. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997; 35: 686-689.
49. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997; 35: 171-175.
50. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631-1637.
51. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-638.
52. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002; 42: 229-236.
53. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999; 19: 149-177.
54. Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil 2008; 30: 1230-1232.
55. Costa E, Guidotti A. Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol 1979; 19: 531-545.
56. Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. Can Med Assoc J 1985; 133: 41-42.
57. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989; 27: 296-301.
58. Ellis KO, Carpenter JF. Mechanism of control of skeletal-muscle contraction by dantrolene sodium. Arch Phys Med Rehabil 1974; 55: 362-369.
59. Herman R, Mayer N, Mecomber SA. Clinical pharmaco--physiology of dantrolene sodium. Am J Phys Med 1972; 51: 296-311.
60. Weiser R, Terenty T, Hudgson P, Weightman D. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner 1978; 221: 123-127.
61. Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil 2010; 24: 293-304.
62. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360.
63. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007; 150: 519-525.
64. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 2009; 9: 59.
65. Hagenbach U, Luz S, Ghafoor N, et al. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45: 551-562.
66. Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag 2010; 6: 59-63.
67. Krassioukov AV, Weaver LC. Episodic hypertension due to autonomic dysreflexia in acute and chronic spinal cord-injured rats. Am J Physiol 1995; 268(5 Pt 2): H2077-H2083.
68. Rivas DA, Chancellor MB, Huang B, Salzman SK. Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents. Neurourol Urodyn 1995; 14: 141-152.
69. Maiorov DN, Fehlings MG, Krassioukov AV. Relationship between severity of spinal cord injury and abnormalities in neurogenic cardiovascular control in conscious rats. J Neurotrauma. 1998; 15: 365-374.
70. Maiorov DN, Weaver LC, Krassioukov AV. Relationship between sympathetic activity and arterial pressure in conscious spinal rats. Am J Physiol 1997; 272(2 Pt 2): H625-H631.
71. Hou S, Duale H, Cameron AA, Abshire SM, Lyttle TS, Rabchevsky AG. Plasticity of lumbosacral propriospinal neurons is associated with the development of autonomic dysreflexia after thoracic spinal cord transection. J Comp Neurol 2008; 509: 382-399.
72. Krassioukov AV, Weaver LC. Morphological changes in sympathetic preganglionic neurons after spinal cord injury in rats. Neuroscience 1996; 70: 211-225.
73. Krenz NR, Weaver LC. Sprouting of primary afferent fibers after spinal cord transection in the rat. Neuroscience 1998; 85: 443-458.
74. Krenz NR, Weaver LC. Changes in the morphology of sympathetic preganglionic neurons parallel the development of autonomic dysreflexia after spinal cord injury in rats. Neuroscience letters. 1998; 243: 61-64.
75. Chau D, Johns DG, Schramm LP. Ongoing and stimulus-evoked activity of sympathetically correlated neurons in the intermediate zone and dorsal horn of acutely spinalized rats. Journal of neurophysiology 2000; 83: 2699-2707.
76. Stjernberg L. Cutaneous vasomotor sensitivity to noradrenalin in spinal and intact man. Scand J Rehabil Med 1986; 18: 127-132.
77. Maiorov DN, Krenz NR, Krassioukov AV, Weaver LC. Role of spinal NMDA and AMPA receptors in episodic hypertension in conscious spinal rats. Am J Physiol 1997; 273(3 Pt 2): H1266-H1274.
78. Cameron AA, Smith GM, Randall DC, Brown DR, Rabchevsky AG. Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia. J Neurosci 2006; 26: 2923-2932.
79. Krenz NR, Meakin SO, Krassioukov AV, Weaver LC. Neutralizing intraspinal nerve growth factor blocks autonomic dysreflexia caused by spinal cord injury. J Neurosci 1999; 19: 7405-7414.
80. Marsh DR, Wong ST, Meakin SO, MacDonald JI, Hamilton EF, Weaver LC. Neutralizing intraspinal nerve growth factor with a trkA-IgG fusion protein blocks the development of autonomic dysreflexia in a clip-compression model of spinal cord injury. J Neurotrauma 2002; 19: 1531-1541.
81. Medicine CfSC. Acute management of autonomic dysreflexia: individuals with spinal cord injury presenting to health-care facilities. J Spinal Cord Med 2002; 25(suppl 1): S67-S88.
82. Torfgard KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994; 8: 701-717.
83. Lee BY, Karmakar MG, Herz BL, Sturgill RA. Autonomic dysreflexia revisited. J Spinal Cord Med 1995; 18: 75-87.
84. Thyberg M, Ertzgaard P, Gylling M, Granerus G. Effect of nifedipine on cystometry-induced elevation of blood pressure in patients with a reflex urinary bladder after a high level spinal cord injury. Paraplegia 1994; 32: 308-313.
85. Braddom RL, Rocco JF. Autonomic dysreflexia. A survey of current treatment. Am J Phys Med Rehabil 1991; 70: 234-241.
86. Chancellor MB, Erhard MJ, Hirsch IH, Stass WE, Jr. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol 1994; 151: 111-113.
87. Vaidyanathan S, Soni BM, Sett P, Watt JW, Oo T, Bingley J. Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and paediatric spinal cord injury patients manifesting recurrent dysreflexic episodes. Spinal Cord 1998; 36: 761-770.
88. Krum H, Louis WJ, Brown DJ, Howes LG. A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res 1992; 2: 83-88.
89. Santajuliana D, Zukowska-Grojec Z, Osborn JW. Contribution of alpha- and beta- adrenoceptors and neuropeptide-Y to autonomic dysreflexia. Clin Auton Res 1995; 5: 91-97.
90. Landrum LM, Thompson GM, Blair RW. Does postsynaptic alpha 1-adrenergic receptor supersensitivity contribute to autonomic dysreflexia? Am J Physiol 1998; 274(4 Pt 2): H1090-H1098.
91. Khastgir J, Drake MJ, Abrams P. Recognition and effective management of autonomic dysreflexia in spinal cord injuries. Expert Opin Pharmacother 2007; 8: 945-956.
92. McMahon D, Tutt M, Cook AM. Pharmacological management of hemodynamic complications following spinal cord injury. Orthopedics 2009; 32: 331.
93. Naftchi NE, Richardson JS. Autonomic dysreflexia: pharmacological management of hypertensive crises in spinal cord injured patients. J Spinal Cord Med 1997; 20: 355-360.
94. Popa C, Popa F, Grigorean VT, et al. Vascular dysfunctions following spinal cord injury. J Med Life 2010; 3: 275-285.
95. Kitzman P. VGLUT1 and GLYT2 labeling of sacrocaudal motoneurons in the spinal cord injured spastic rat. Exp Neurol 2007; 204: 195-204.
96. Kitzman PH, Uhl TL, Dwyer MK. Gabapentin suppresses spasticity in the spinal cord-injured rat. Neuroscience 2007; 149: 813-821.
97. Rabchevsky AG, Patel SP, Duale H, Lyttle TS, O'Dell CR, Kitzman PH. Gabapentin for spasticity & autonomic dysreflexia after severe spinal cord injury. Spinal Cord 2011; 49: 99-105.
98. Rabchevsky AG, Patel SP, Lyttle TS, O'Dell CR, Kitzman PH. Effects of chronic versus acute gabapentin administration on spasticity & autonomic dysreflexia after severe spinal cord injury. J Neurotrauma 2010; 26: A-73. Abstract.